FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020304503> ?p ?o ?g. }

• W2020304503 endingPage "1783" @default.
• W2020304503 startingPage "1773" @default.
• W2020304503 abstract "Abstract Purpose: To identify mediators of glioblastoma antiangiogenic therapy resistance and target these mediators in xenografts. Experimental Design: We conducted microarray analysis comparing bevacizumab-resistant glioblastomas (BRG) with pretreatment tumors from the same patients. We established novel xenograft models of antiangiogenic therapy resistance to target candidate resistance mediator(s). Results: BRG microarray analysis revealed upregulation versus pretreatment of receptor tyrosine kinase c-Met, which underwent further investigation because of its prior biologic plausibility as a bevacizumab resistance mediator. BRGs exhibited increased hypoxia versus pretreatment in a manner correlating with their c-Met upregulation, increased c-Met phosphorylation, and increased phosphorylation of c-Met–activated focal adhesion kinase and STAT3. We developed 2 novel xenograft models of antiangiogenic therapy resistance. In the first model, serial bevacizumab treatment of an initially responsive xenograft generated a xenograft with acquired bevacizumab resistance, which exhibited upregulated c-Met expression versus pretreatment. In the second model, a BRG-derived xenograft maintained refractoriness to the MRI tumor vasculature alterations and survival-promoting effects of bevacizumab. Growth of this BRG-derived xenograft was inhibited by a c-Met inhibitor. Transducing these xenograft cells with c-Met short hairpin RNA inhibited their invasion and survival in hypoxia, disrupted their mesenchymal morphology, and converted them from bevacizumab-resistant to bevacizumab-responsive. Engineering bevacizumab-responsive cells to express constitutively active c-Met caused these cells to form bevacizumab-resistant xenografts. Conclusion: These findings support the role of c-Met in survival in hypoxia and invasion, features associated with antiangiogenic therapy resistance, and growth and therapeutic resistance of xenografts resistant to antiangiogenic therapy. Therapeutically targeting c-Met could prevent or overcome antiangiogenic therapy resistance. Clin Cancer Res; 19(7); 1773–83. ©2012 AACR." @default.
• W2020304503 created "2016-06-24" @default.
• W2020304503 creator A5003506511 @default.
• W2020304503 creator A5015074174 @default.
• W2020304503 creator A5020870956 @default.
• W2020304503 creator A5025568576 @default.
• W2020304503 creator A5027248843 @default.
• W2020304503 creator A5030571525 @default.
• W2020304503 creator A5035709171 @default.
• W2020304503 creator A5035762375 @default.
• W2020304503 creator A5049126969 @default.
• W2020304503 creator A5052983963 @default.
• W2020304503 creator A5053242094 @default.
• W2020304503 creator A5055802741 @default.
• W2020304503 creator A5060105335 @default.
• W2020304503 creator A5061192105 @default.
• W2020304503 creator A5069903324 @default.
• W2020304503 creator A5080355228 @default.
• W2020304503 creator A5088787388 @default.
• W2020304503 date "2013-04-01" @default.
• W2020304503 modified "2023-10-18" @default.
• W2020304503 title "Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance" @default.
• W2020304503 cites W1649526546 @default.
• W2020304503 cites W1968107383 @default.
• W2020304503 cites W1977430640 @default.
• W2020304503 cites W1981963681 @default.
• W2020304503 cites W1987606222 @default.
• W2020304503 cites W1996810856 @default.
• W2020304503 cites W2003697699 @default.
• W2020304503 cites W2011138678 @default.
• W2020304503 cites W2017150024 @default.
• W2020304503 cites W2017322644 @default.
• W2020304503 cites W2018016372 @default.
• W2020304503 cites W2021074358 @default.
• W2020304503 cites W2022961329 @default.
• W2020304503 cites W2035301061 @default.
• W2020304503 cites W2039013742 @default.
• W2020304503 cites W2044344195 @default.
• W2020304503 cites W2047392162 @default.
• W2020304503 cites W2048043668 @default.
• W2020304503 cites W2063553928 @default.
• W2020304503 cites W2067845233 @default.
• W2020304503 cites W2091506455 @default.
• W2020304503 cites W2092409918 @default.
• W2020304503 cites W2093783077 @default.
• W2020304503 cites W2097390500 @default.
• W2020304503 cites W2099688399 @default.
• W2020304503 cites W2101332957 @default.
• W2020304503 cites W2101918466 @default.
• W2020304503 cites W2107132417 @default.
• W2020304503 cites W2113282518 @default.
• W2020304503 cites W2113942802 @default.
• W2020304503 cites W2116715687 @default.
• W2020304503 cites W2118362228 @default.
• W2020304503 cites W2127745545 @default.
• W2020304503 cites W2129512401 @default.
• W2020304503 cites W2138896702 @default.
• W2020304503 cites W2140088548 @default.
• W2020304503 cites W2144718958 @default.
• W2020304503 cites W2150291313 @default.
• W2020304503 cites W2156480607 @default.
• W2020304503 doi "https://doi.org/10.1158/1078-0432.ccr-12-1281" @default.
• W2020304503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3618605" @default.
• W2020304503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23307858" @default.
• W2020304503 hasPublicationYear "2013" @default.
• W2020304503 type Work @default.
• W2020304503 sameAs 2020304503 @default.
• W2020304503 citedByCount "173" @default.
• W2020304503 countsByYear W20203045032013 @default.
• W2020304503 countsByYear W20203045032014 @default.
• W2020304503 countsByYear W20203045032015 @default.
• W2020304503 countsByYear W20203045032016 @default.
• W2020304503 countsByYear W20203045032017 @default.
• W2020304503 countsByYear W20203045032018 @default.
• W2020304503 countsByYear W20203045032019 @default.
• W2020304503 countsByYear W20203045032020 @default.
• W2020304503 countsByYear W20203045032021 @default.
• W2020304503 countsByYear W20203045032022 @default.
• W2020304503 countsByYear W20203045032023 @default.
• W2020304503 crossrefType "journal-article" @default.
• W2020304503 hasAuthorship W2020304503A5003506511 @default.
• W2020304503 hasAuthorship W2020304503A5015074174 @default.
• W2020304503 hasAuthorship W2020304503A5020870956 @default.
• W2020304503 hasAuthorship W2020304503A5025568576 @default.
• W2020304503 hasAuthorship W2020304503A5027248843 @default.
• W2020304503 hasAuthorship W2020304503A5030571525 @default.
• W2020304503 hasAuthorship W2020304503A5035709171 @default.
• W2020304503 hasAuthorship W2020304503A5035762375 @default.
• W2020304503 hasAuthorship W2020304503A5049126969 @default.
• W2020304503 hasAuthorship W2020304503A5052983963 @default.
• W2020304503 hasAuthorship W2020304503A5053242094 @default.
• W2020304503 hasAuthorship W2020304503A5055802741 @default.
• W2020304503 hasAuthorship W2020304503A5060105335 @default.
• W2020304503 hasAuthorship W2020304503A5061192105 @default.
• W2020304503 hasAuthorship W2020304503A5069903324 @default.
• W2020304503 hasAuthorship W2020304503A5080355228 @default.
• W2020304503 hasAuthorship W2020304503A5088787388 @default.
• W2020304503 hasBestOaLocation W20203045031 @default.

• next